Literature DB >> 26364518

Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma.

Finn Ole Larsen1, Dan Taksony Solyom Hoegdall1, Estrid Hoegdall2, Dorte Nielsen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26364518     DOI： 10.3109/0284186X.2015.1080858

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  4 in total

1.  Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.

Authors:  Sergey V Silkin; Sergey S Startsev; Marina E Krasnova; Grigory A Raskin; Natalia V Mitiushkina; Aglaya G Iyevleva; Anna P Sokolenko; Evgeny N Imyanitov
Journal:  J Gastrointest Cancer       Date:  2016-12

2.  Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.

Authors:  Fangqiang Wei; Donghun Shin; Xiujun Cai
Journal:  Int J Clin Oncol       Date:  2017-12-30       Impact factor: 3.402

Review 3.  Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.

Authors:  Sandra Pavicevic; Sophie Reichelt; Deniz Uluk; Isabella Lurje; Cornelius Engelmann; Dominik P Modest; Uwe Pelzer; Felix Krenzien; Nathanael Raschzok; Christian Benzing; Igor M Sauer; Sebastian Stintzing; Frank Tacke; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Georg Lurje
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

Review 4.  Systemic treatment options for advanced biliary tract carcinoma.

Authors:  Changqing Xie; Nicole A McGrath; Cecilia Monge Bonilla; Jianyang Fu
Journal:  J Gastroenterol       Date:  2020-08-03       Impact factor: 7.527
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.